CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel,
proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic
infectious diseases, announced today that the Honorable Randall R. Rader has agreed to serve as the Chair of the company's
Intellectual Property Committee.
“Judge Rader is a world-renowned expert and leader in intellectual property law. His tremendous knowledge, experience and
strategic insights will help guide the development of our patent and trademark programs around the world,” said Daniel Passeri,
M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma. "Having such a highly experienced and well-respected legal
scholar and luminary help guide the progress of our IP portfolio underscores our commitment to increase shareholder value by
protecting the leadership position of our Immuno-STAT Biologics™ platform.”
“I am pleased to be working with Cue Biopharma during a period of strong growth for the Company,” said Judge Rader. “Cue
Biopharma’s biologics platform holds tremendous potential as a breakthrough approach for selectively controlling the modulation of
disease-associated T cells, and as such, the Company is developing a substantial and growing IP portfolio to protect it. I look
forward to working closely with the leadership team to help establish and foster strong, worldwide protection of both the patent
and trademark rights."
For twenty-six years (1988 to 2014), Judge Rader served as a United States Federal trial and appellate judge. During that time,
he served as a judge on the United States Court of Appeals for the Federal Circuit from 1994 to 2014, including presiding as Chief
Judge from 2010 to 2014. Throughout his tenure, Judge Rader authored pivotal decisions in nearly every area of patent and trademark
law. He also conducted jury trials as a District Court Judge sitting by designation in California, New York, Texas and
Illinois.
Prior to entering the Federal Judiciary, Judge Rader served as the Chief Counsel (Majority and Minority) to the Senate Judiciary
Committee Subcommittees, where he contributed to important intellectual property legislation including the Bayh-Dole Act, the
Hatch-Waxman Act, the Berne Convention Implementation Act, and the Federal Courts Improvement Act. From 1992 to present, Judge
Rader has also taught law school as an Adjunct Professor of Patent Law and Comparative Patent Law at the University of Virginia,
Georgetown University and the George Washington University. He also has taught law courses in Munich, Tokyo, Delhi, Taipei, London
and Beijing, and currently serves on the Law School Faculty at Tsinghua University in Beijing. He is the author of a Patent Law
casebook for West Publishing, the Fifth Edition of which is currently in press.
Following his retirement from the Federal Judiciary in 2014, Judge Rader has served as an ICC arbitrator and recently helped
establish the International Arbitration Center in Tokyo (IACT) bringing together dozens of the most qualified IP experts and former
judges in the world from Europe, Korea, China, and Japan as well as the USA.
About Cue Biopharma
Cue Biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to
selectively modulate the human immune system to treat a broad range of cancers, autoimmune and chronic infectious diseases. We
design biologics to engage and modulate the activity of disease-associated T cells in the patient’s body, with the goal of offering
significant therapeutic benefits while potentially minimizing or eliminating unwanted side effects.
We believe our selective biologics allow us to target antigen-specific T cell populations in a variety of indications using a
peptide – MHC complex for delivering T cell modulating effectors, such as IL-2. Once a biologic has been optimized, our approach
offers the potential for readily exchanging peptides to target different T cell populations and indications using
previously-validated drug frameworks developed from the Immuno-STATTM (Selective Targeting and Alteration of T cells)
platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery
to clinical validation more rapidly and cost-efficiently than current industry standard timelines and costs.
Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board
(SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
For more information, visit www.cuebio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor”
created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,”
“will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,”
“likely” or other comparable terms. All statements other than statements of historical facts included in this press release
regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements.
Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug
development efforts, including study results, our expectations regarding regulatory developments and expected future operating
results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to
the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many
of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements
include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability;
our ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for our product candidates
and the breadth of any approved indication; negative or inconclusive results from our clinical studies or serious and unexpected
drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in
regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the
FDA; our reliance on licensors, collaborations and strategic alliances; our ability to obtain adequate financing to fund our
business operations in the future; and the other risks and uncertainties described in the Risk Factors and in Management's
Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form
10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is
based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result
of new information, future developments or otherwise.
Investor Contact:
John Woolford
Westwicke Partners
443-213-0506
Media Contact:
Cory Tromblee
Sam Brown Inc.
617-571-7220
